The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma.
 
Andreas Pahl
Employment - Heidelberg Pharma
Leadership - Heidelberg Pharma
Stock and Other Ownership Interests - Heidelberg Pharma
Patents, Royalties, Other Intellectual Property - Heidelberg Pharma Research GmbH
 
Jonathan Ko
No Relationships to Disclose
 
Christian Breunig
Employment - Heidelberg Pharma
Stock and Other Ownership Interests - Heidelberg Pharma
 
Vianiuhini Figueroa
No Relationships to Disclose
 
Nicola Lehners
No Relationships to Disclose
 
Anja Baumann
No Relationships to Disclose
 
Anikó Pálfi
Employment - Heidelberg Pharma
Stock and Other Ownership Interests - Heidelberg Pharma
Patents, Royalties, Other Intellectual Property - Heidelberg Pharma Research GmbH
 
Christoph Mueller
Employment - Heidelberg Pharma
Stock and Other Ownership Interests - Heidelberg Pharma
Patents, Royalties, Other Intellectual Property - Heidelberg Pharma Research GmbH
 
Christian Lutz
Employment - Heidelberg Pharma
Stock and Other Ownership Interests - Heidelberg Pharma
Patents, Royalties, Other Intellectual Property - Heidelberg Pharma Research GmbH
 
Torsten Hechler
Employment - Heidelberg Pharma
Stock and Other Ownership Interests - Heidelberg Pharma
Patents, Royalties, Other Intellectual Property - Heidelberg Pharma Research GmbH
 
Michael Kulke
Employment - Heidelberg Pharma
Stock and Other Ownership Interests - Heidelberg Pharma
Patents, Royalties, Other Intellectual Property - Heidelberg Pharma Research GmbH
 
Carsten Mueller-Tidow
No Relationships to Disclose
 
Hartmut Goldschmidt
Honoraria - Art tempi; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen-Cilag; Novartis
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Sanofi; Takeda (Inst)
Speakers' Bureau - Art tempi; Bristol-Myers Squibb; Celgene; Chugai Pharma Europe; Janssen; Novartis
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma Europe (Inst); Janssen (Inst); Mundipharma (Inst); Novartis (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Novartis; Sanofi; Takeda
 
Marc Raab
Honoraria - Bristol-Myers Squibb; Celgene; Janssen; Novartis; Takeda
Research Funding - Heidelberg Pharma (Inst)